NASDAQ:AUPH

Aurinia Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy AUPH

*Your capital is at risk

$15.67

+0.280 (+1.82%)

At Close: Jun 03, 2026

Aurinia Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 84.88. In total, the insiders bought 10.44M and sold 1.48M AUPH shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	84.88
● Buy	10.44M shares
● Sell	1.48M shares
71% Buy Activity Weak Positive Correlation
Buy Signal Medium Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 84.88. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 02, 2026 Buy	Short Put Options (potential obligation to buy) J-Other	Tang Kevin Chief Executive Officer	CEO / President	10 000 Value: $150.0K
Jun 02, 2026 Buy	Common Shares P-Purchase	Tang Kevin Chief Executive Officer	CEO / President	206 005 Value: $3.15M
Jun 01, 2026 Buy	Common Shares P-Purchase	Tang Kevin Chief Executive Officer	CEO / President	343 521 Value: $5.25M
Jun 01, 2026 Buy	Common Shares P-Purchase	Tang Kevin Chief Executive Officer	CEO / President	99 Value: $2K
May 29, 2026 Buy	Common Shares P-Purchase	Tang Kevin Chief Executive Officer	CEO / President	2 299 Value: $35.3K
May 29, 2026 Buy	Common Shares P-Purchase	Tang Kevin Chief Executive Officer	CEO / President	262 682 Value: $4.02M
May 18, 2026 Buy	Employee Stock Option (right to buy) A-Award	Cole Ryan Chief Operating Officer	C-Suite Officer	70 230 Value: $1.07M
May 18, 2026 Buy	Common Stock A-Award	Cole Ryan Chief Operating Officer	C-Suite Officer	116 144 Value: $1.81M
May 18, 2026 Buy	Employee Stock Option (right to buy) A-Award	Hearne Michael S Chief Financial Officer	C-Suite Officer	70 230 Value: $1.07M
May 18, 2026 Buy	Common Stock A-Award	Hearne Michael S Chief Financial Officer	C-Suite Officer	116 144 Value: $1.81M
May 18, 2026 Buy	Common Stock A-Award	Robertson Stephen P. Chief Legal Officer	Officer	115 541 Value: $1.80M
Mar 23, 2026 Buy	Common Stock J-Other	Hearne Michael S Officer	Officer	0 Value: $0
Mar 23, 2026 Buy	Common Stock J-Other	Cole Ryan Officer	Officer	0 Value: $0
Mar 06, 2026 Sell	Common Stock F-InKind	Keenan Greg SVP, Chief Medical Officer	Officer	8 069 Value: $115.5K
Mar 03, 2026 Buy	Common Shares P-Purchase	Tang Kevin Director	Director	184 208 Value: $2.62M
Mar 02, 2026 Sell	Common Stock F-InKind	Robertson Stephen P. EVP, General Counsel	Officer	36 525 Value: $519.0K
Mar 02, 2026 Sell	Common Stock F-InKind	Greenleaf Peter Chief Executive Officer	CEO / President	100 890 Value: $1.43M
Mar 02, 2026 Sell	Common Stock F-InKind	Donley Matthew Maxwell Chief Operating Officer	C-Suite Officer	40 761 Value: $579.2K
Mar 02, 2026 Sell	Common Stock F-InKind	Miller Joseph M Chief Financial Officer	C-Suite Officer	37 511 Value: $533.0K
Mar 02, 2026 Buy	Common Shares P-Purchase	Tang Kevin Director	Director	83 561 Value: $1.20M
Mar 02, 2026 Buy	Common Shares P-Purchase	Tang Kevin Director	Director	115 792 Value: $1.65M
Feb 27, 2026 Buy	Employee Stock Option (right to buy) A-Award	Robertson Stephen P. EVP, General Counsel	Officer	98 813 Value: $1.38M
Feb 27, 2026 Buy	Common Stock A-Award	Robertson Stephen P. EVP, General Counsel	Officer	59 090 Value: $837.3K
Feb 27, 2026 Buy	Employee Stock Option (right to buy) A-Award	Keenan Greg SVP, Chief Medical Officer	Officer	67 870 Value: $948.1K
Feb 27, 2026 Buy	Common Stock A-Award	Keenan Greg SVP, Chief Medical Officer	Officer	40 586 Value: $575.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AURINIA PHARMACEUTICALS INC

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada....

Read Full Profile Here